Navigation Links
New molecular insight into amboebic dysentery

In the June 15th issue of G&D, Dr. Sinisa Urban (Johns Hopkins University School of Medicine) and colleagues reveal a potential role for the rhomboid enzyme, EhROM1, in the pathogenesis of the enteric protozoan parasite, E. histolytica. This discovery posits EhROM1 as a prospective target in the treatment of amoebic dysentery, which affects 1/10th of the global population (~500 million people) and represents the second most common disease in the world.

"New drug targets are needed for amebiasis as current treatments have associated toxicities and drug resistance is a concern." said Dr. Upinder Singh, a clinician at Stanford University and co-author of the study.

E. histolytica is a single-celled intestinal parasite that infects the lower GI tract, causing amoebiasis, and can invade the intestinal wall and spread to the bloodstream, causing potentially fatal amoebic liver abscesses. The parasite is transmitted through fecally contaminated food or water, and is a major public health threat in the developing world.

Dr. Urban and colleagues uncovered new insight into the activity of E. histolytica's single rhomboid protease protein, EhROM1, which suggests that it helps the parasite evade the host's immune response. In order to escape immune detection, E. histolytica trophozoites concentrate immune system-eliciting surface proteins towards the rear of the cell and then expel them. Dr. Urban's team discovered that EhROM1 processes surface lectin proteins, and collaborators at Stanford University found that it re-localizes posteriorly during lectin shedding.

These findings suggest that EhROM1 facilitates lectin shedding and host immune system evasion by this pathogenic parasite. Dr. Urban is excited by the new findings, since "Enzymes have served as particularly successful drug targets in the past, so it's exciting to discover an ameba rhomboid enzyme with similar properties as a malaria rhomboid. We're hopeful that with additional work, we will be able to develop rhomboid inhibitors and evaluate if they could be applied as a more general anti-parasitic strategy in the future."


Contact: Heather Cosel-Pieper
Cold Spring Harbor Laboratory

Related medicine news :

1. Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer
2. Molecular insight begins Trofex Ph. 1 trial for detection of metastatic prostate cancer
3. Siemens Showcases Innovative Leadership in Molecular Imaging at SNM 2008
4. Xceed Molecular Licenses Signature from Moffitt Cancer Center and Adds Moffitt to Strategic Collaborator Program
5. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
6. Research reveals molecular fingerprint of cocaine addiction
7. SNM hosts 55th Annual Meeting of Nuclear Medicine and Molecular Imaging Research
8. Study identifies molecular response of cartilage to injury
9. Molecular change may reveal risk of leukemia relapse
10. Study Details New Molecular Approach to Preventing Alzheimers
11. Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point Recovery, ... together on Thanksgiving Day to share the things that they are most grateful ... Point YouTube channel, patients displayed what they wrote on index cards, describing the ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
(Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
Breaking Medicine Technology: